LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

30.63 -6.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.56

Max

31.32

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.8M

-81M

Pelnas, tenkantis vienai akcijai

-0.88

Pelno marža

-18,560.15

Darbuotojai

437

EBITDA

-6.9M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+154.89% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-50M

3.2B

Ankstesnė atidarymo kaina

37.05

Ankstesnė uždarymo kaina

30.63

Naujienos nuotaikos

By Acuity

50%

50%

170 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-11 23:48; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

2025-05-11 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

2025-05-11 23:45; UTC

Rinkos pokalbiai

Oil Rises Amid Improved Market Mood -- Market Talk

2025-05-11 23:38; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Aristocrat Has Significant Firepower for M&A -- Market Talk

2025-05-11 23:36; UTC

Rinkos pokalbiai

Global Markets Uncertain About US-China Trade News -- Market Talk

2025-05-11 23:35; UTC

Rinkos pokalbiai

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

2025-05-11 23:33; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

2025-05-11 23:32; UTC

Svarbiausios naujienos

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

2025-05-11 22:44; UTC

Rinkos pokalbiai

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

2025-05-11 22:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

2025-05-11 20:19; UTC

Svarbiausios naujienos

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

2025-05-11 16:00; UTC

Svarbiausios naujienos

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

2025-05-11 11:00; UTC

Svarbiausios naujienos

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

2025-05-11 08:00; UTC

Svarbiausios naujienos

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

2025-05-11 01:00; UTC

Svarbiausios naujienos

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

2025-05-11 01:00; UTC

Svarbiausios naujienos

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

2025-05-10 21:54; UTC

Svarbiausios naujienos

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

2025-05-10 17:12; UTC

Svarbiausios naujienos

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

2025-05-10 15:41; UTC

Svarbiausios naujienos

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

2025-05-10 12:00; UTC

Svarbiausios naujienos

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

2025-05-10 09:30; UTC

Svarbiausios naujienos

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

2025-05-10 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-05-10 03:52; UTC

Svarbiausios naujienos

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

2025-05-09 23:51; UTC

Įsigijimai, susijungimai, perėmimai

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

2025-05-09 22:06; UTC

Rinkos pokalbiai

Arm Holdings Remains a Strong Growth Story -- Market Talk

2025-05-09 21:37; UTC

Svarbiausios naujienos

U.S. Sets August Deadline for Debt Ceiling -- WSJ

2025-05-09 21:10; UTC

Svarbiausios naujienos

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

2025-05-09 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-05-09 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-05-09 20:42; UTC

Svarbiausios naujienos

Stocks Get a Break From Trade Chaos -- WSJ

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

154.89% į viršų

12 mėnesių prognozė

Vidutinis 78.2 USD  154.89%

Aukščiausias 100 USD

Žemiausias 53 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

11

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

170 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.